Summary
Slowly and steadily we are seeing positive news trickle in from Ranbaxy!!
This indicates that measures taken to put their house in order are finally showing results.
The latest approval to market Rocaltrol for which Ranbaxy will be the 1st to launch the Generic version will be good addition to the bottom line.
1st Generic always has a good advantage in terms of market capturing abilities.
With a 70 million market open to capture, getting 35 - 40 million in 18 - 24 months is not impossible.
Analysis
Ranbaxy with its new Parent Daiichi Sankyo is very seriously working towards a turn around.
Rocaltrol & other news posted by me in the past are a sure sign of that.
At current levels Ranbaxy will be good buy as over the medium term there is considerable upward movement possibility.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
